“I survived cancer as a child and now I’m working to defeat it” – Andrew’s story 28 Nov 2023 Andrew Wicks, a PhD student at The Institute of Cancer Research, knows firsthand what it’s like to face cancer. Diagnosed with acute lymphoblastic leukaemia (ALL) at the age of 12, he went through years of treatment before getting the all-clear. Now, wanting to help others with cancer, he is carrying out research in our Breast Cancer Research Division. Here, he shares his story. Find out more Show/Hide
How do we overcome treatment resistance in a sarcoma cancer with already limited treatment options? 25 Jul 2023 Leiomyosarcoma is a type of soft tissue sarcoma that is hard-to-treat and associated with a poor prognosis. Scientists at the ICR are working to better understand the biology of this cancer to develop more targeted and effective treatment options. Elena Daviter-Nowell spoke to Dr Will Kerrison about the future of cancer treatment for patients with leiomyosarcoma. Find out more Show/Hide
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 04 Jun 2021 The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough. Find out more Show/Hide
ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation 07 Jun 2017
BRCA-targeting drug olaparib could offer hope for women with advanced breast cancer with inherited mutation 27 Feb 2017